Evidence map›Paper›PMID 37869089›Full record

ArticleFrontiers in oncology2023

A plasma miRNA-based classifier for small cell lung cancer diagnosis.

Michela Saviana, Giulia Romano, Joseph McElroy, Giovanni Nigita, Rosario Distefano, Robin Toft, Federica Calore, Patricia Le, Daniel Del Valle Morales, Sarah Atmajoana and 5 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 2 countries.

Michela SavianaDepartment of Internal Medicine, Division of Pulmonary Diseases and Critical Care Medicine, Virginia Commonwealth University, Richmond, VA, United States.
Giulia RomanoDepartment of Internal Medicine, Division of Pulmonary Diseases and Critical Care Medicine, Virginia Commonwealth University, Richmond, VA, United States.
Joseph McElroyCenter for Biostatistics, The Ohio State University, Columbus, OH, United States.
Giovanni NigitaDepartment of Cancer Biology and Genetics, The Ohio State University, Columbus, OH, United States.
Rosario DistefanoDepartment of Cancer Biology and Genetics, The Ohio State University, Columbus, OH, United States.
Robin ToftDepartment of Internal Medicine, Division of Pulmonary Diseases and Critical Care Medicine, Virginia Commonwealth University, Richmond, VA, United States.
Federica CaloreDepartment of Cancer Biology and Genetics, The Ohio State University, Columbus, OH, United States.
Patricia LeDepartment of Internal Medicine, Division of Pulmonary Diseases and Critical Care Medicine, Virginia Commonwealth University, Richmond, VA, United States.
Daniel Del Valle MoralesDepartment of Internal Medicine, Division of Pulmonary Diseases and Critical Care Medicine, Virginia Commonwealth University, Richmond, VA, United States.
Sarah AtmajoanaVanderbilt University Medical Center and Tennessee Valley Healthcare System, Nashville, TN, United States.
Stephen DeppenVanderbilt University Medical Center and Tennessee Valley Healthcare System, Nashville, TN, United States.
Kai WangInstitute for System Biology, Seattle, WA, United States.
L James LeeDepartment of Chemical and Biomolecular Engineering, The Ohio State University, Columbus, OH, United States.
Mario AcunzoDepartment of Internal Medicine, Division of Pulmonary Diseases and Critical Care Medicine, Virginia Commonwealth University, Richmond, VA, United States.
Patrick Nana-SinkamDepartment of Internal Medicine, Division of Pulmonary Diseases and Critical Care Medicine, Virginia Commonwealth University, Richmond, VA, United States.
Virginia Commonwealth University · USThe Ohio State University · USInstitute for Systems Biology · USSapienza University of Rome · ITVanderbilt University Medical Center · USVA Tennessee Valley Healthcare System · US

Funding

Institutional Career Development CoreKL2TR002648 · NCATS · VIRGINIA COMMONWEALTH UNIVERSITY · PI NANASINKAM, SERGE PATRICK, SANYAL, ARUN J · 2018 to 2022
$3.7M
Translational Research Center in Lung Cancer Disparities (TRACER)P20CA252717 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI HUGHES-HALBERT, CHANITA A. · 2021 to 2023
$3.2M
Extracellular Vesicles in Small Cell Lung Cancer Early DetectionU01CA213330 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI LEE, LY JAMES, NANASINKAM, SERGE PATRICK · 2017 to 2021
$2.7M
NCATS NIH HHS KL2 TR002648NCI NIH HHS P20 CA252717NCI NIH HHS U01 CA213330
6 · The paper itself

Abstract

Introduction: Small cell lung cancer (SCLC) is characterized by poor prognosis and challenging diagnosis. Screening in high-risk smokers results in a reduction in lung cancer mortality, however, screening efforts are primarily focused on non-small cell lung cancer (NSCLC). SCLC diagnosis and surveillance remain significant challenges. The aberrant expression of circulating microRNAs (miRNAs/miRs) is reported in many tumors and can provide insights into the pathogenesis of tumor development and progression. Here, we conducted a comprehensive assessment of circulating miRNAs in SCLC with a goal of developing a miRNA-based classifier to assist in SCLC diagnoses. Methods: We profiled deregulated circulating cell-free miRNAs in the plasma of SCLC patients. We tested selected miRNAs on a training cohort and created a classifier by integrating miRNA expression and patients' clinical data. Finally, we applied the classifier on a validation dataset. Results: We determined that miR-375-3p can discriminate between SCLC and NSCLC patients, and between SCLC and Squamous Cell Carcinoma patients. Moreover, we found that a model comprising miR-375-3p, miR-320b, and miR-144-3p can be integrated with race and age to distinguish metastatic SCLC from a control group. Discussion: This study proposes a miRNA-based biomarker classifier for SCLC that considers clinical demographics with specific cut offs to inform SCLC diagnosis.

Indexed as

biomarkersclassifiermicroRNAsoncologysmall cell lung cancer

Identifiers

PMID37869089
PMCPMC10585112
OpenAlexW4387366282

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.